Correlation of BCL-6, MYC and p53 gene abnormalities with immunological subtypes and prognosis of diffuse large B-cell lymphoma

Chinese Journal of Medical Genetics

Volumn 29, Issue 5, 2012, Pages 576-581

  Sun, Guan Xing ^a   Cao, Xiang Shan ^a   Li, Qing ^a   Wang, Zhi Lin ^a  

^a SOOCHOW UNIVERSITY   (China)

Author keywords

BCL 6 gene; Diffuse large cell lymphoma; Immunophenotype; MYC gene; p53 gene; Prognosis

Indexed keywords

CD20 ANTIGEN; CD3 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; KI 67 ANTIGEN; MYC PROTEIN; PROTEIN BCL 2; PROTEIN BCL 6; PROTEIN P53;

ARTICLE; CANCER CLASSIFICATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE REARRANGEMENT; HUMAN; IMMUNOHISTOCHEMISTRY; INTERPHASE FLUORESCENCE IN SITU HYBRIDIZATION; LARGE CELL LYMPHOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION;

DNA-BINDING PROTEINS; FEMALE; GENES, P53; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MYC;

EID: 84869790441     PISSN: 10039406     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.1003-9406.2012.05.017     Document Type: Article

References (20)

1. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 2000,403:503-511. (Pubitemid 30082188)
2. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood, 2007,109:1857-1861. (Pubitemid 46348180)
3. Kramer MH, Hermans J, Wijburg E, et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood, 1998,92:3152-3162. (Pubitemid 28492322)
4. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 2004,103:275-282. (Pubitemid 38029949)
5. Iqbal J, Greiner TC, Patel K, et al. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia, 2007,21:2332-2343. (Pubitemid 350011706)
6. Shustik J, Han G, Farinha P, et al. Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP. Haematologica, 2010,95:96-101.
7. Offit K, Coco FL, Louie DC, et al. Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma. N Engl J Med, 1994,331:74-80.
8. Barrans SL, O'Connor S, Evans P, et al. Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma. Br J Haematol, 2002,117:322-332. (Pubitemid 34451147)
9. Li Y, Wang GP, Xi YF, et al. State of chromosome 3q27 and different subtypes of diffuse large B-cell lymphoma and their prognostic correlation. Chin J Pathol, 2009,38:231-236.
10. Chen Z, Du Z, Chen J, et al. Prognostic evaluation of immunohistochemical profiles in diffuse large B-cell lymphoma: a Chinese study. Med Oncol, 2011,28:241-248.
11. Pasqualucci L, Migliazza A, Basso K, et al. Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. Blood, 2003,101:2914-2923. (Pubitemid 36857975)
12. Ueda C, Uchiyama T, Ohno H. Immunoglobulin (Ig)/BCL6 versus non-Ig/BCL6 gene fusion in diffuse large B-cell lymphoma corresponds to a high-versus low-level expression of BCL6 mRNA. Blood, 2002,99:2624-2625. (Pubitemid 34525459)
13. Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood, 2009,114:3533-3537.
14. Yoon SO, Jeon YK, Paik JH, et al. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type. Histopathology, 2008,53:205-217. (Pubitemid 352032771)
15. Snuderl M, Kolman OK, Chen YB, et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol, 2010,34:327-340.
16. Nakamura N, Nakamine H, Tamaru J, et al. The distinction between Burkitt lymphoma and diffuse large B-cell lymphoma with MYC rearrangement. Mod Pathol, 2002,15:771-776. (Pubitemid 34787314)
17. Nilsson JA, Cleveland JL. Myc pathways provoking cell suicide and cancer. Oncogene, 2003,22:9007-9021. (Pubitemid 38121701)
18. Egle A, Harris AW, Bouillet P, et al. Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc Natl Acad Sci U S A, 2004,101:6164-6169. (Pubitemid 38520545)
19. Young KH, Leroy K, Moller MB, et al. Structural profiles of p53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood, 2008,112:3088-3098.
20. Feng LJ, Zhang GY, Zhang GP, et al. Association of absence of p53 gene and chromosome 13q14 variation with prognosis of primary gastrointestinal lymphoma. Chin J Dig, 2010,30:149-153.